Qingdao Haier Biomedical Co Ltd
SSE:688139
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Qingdao Haier Biomedical Co Ltd
EPS (Diluted)
Qingdao Haier Biomedical Co Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Qingdao Haier Biomedical Co Ltd
SSE:688139
|
EPS (Diluted)
¥0
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
EPS (Diluted)
¥5
|
CAGR 3-Years
32%
|
CAGR 5-Years
49%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
EPS (Diluted)
¥1
|
CAGR 3-Years
11%
|
CAGR 5-Years
2%
|
CAGR 10-Years
15%
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
EPS (Diluted)
¥6
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
Andon Health Co Ltd
SZSE:002432
|
EPS (Diluted)
¥4
|
CAGR 3-Years
-50%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
EPS (Diluted)
¥1
|
CAGR 3-Years
-4%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Qingdao Haier Biomedical Co Ltd
Glance View
Qingdao Haier Biomedical Co Ltd, nestled within the vibrant hub of Qingdao, China, has been a dynamic player in the life sciences and healthcare industry since its inception. Originally part of the expansive Haier Group, known globally for its household appliances, Haier Biomedical has carved out a niche by focusing intently on the intersection of cold chain logistics and biomedical engineering. Its product line is built around the essential needs of the healthcare, pharmaceutical, and research sectors, where precise temperature control is not just an operational nicety but a critical necessity. The company's range of equipment—from ultra-low temperature freezers to blood bank refrigerators and smart cold storage solutions—acts as the backbone for preserving biological samples, vaccines, and medications. By pioneering smart technology integration within these systems, the company effectively meets stringent global standards, ensuring the safety and efficacy of conserved biological materials. The commercial success of Haier Biomedical stems from its dual strategy of deeply engaging with international markets while continuously innovating its product offerings. The company makes money by selling its high-tech storage and transport solutions to a vast array of clients including hospitals, research laboratories, and pharmaceutical manufacturers around the globe. This revenue model is bolstered by its ability to tap into an ever-growing demand for efficient biological storage, driven by global health initiatives and the rising importance of biotech advancements. Meanwhile, its continuous investment in R&D has positioned it as a leader in smart cold chain logistics, enabling it to adapt swiftly to the rapidly evolving landscape of global healthcare needs. By leveraging its technical expertise and maintaining strong relationships with sector stakeholders across the world, Haier Biomedical consistently achieves a robust financial performance, underpinned by its commitment to quality and innovation in the biomedical field.
See Also
What is Qingdao Haier Biomedical Co Ltd's EPS (Diluted)?
EPS (Diluted)
0.8
CNY
Based on the financial report for Dec 31, 2025, Qingdao Haier Biomedical Co Ltd's EPS (Diluted) amounts to 0.8 CNY.
What is Qingdao Haier Biomedical Co Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
-7%
Over the last year, the EPS (Diluted) growth was -31%. The average annual EPS (Diluted) growth rates for Qingdao Haier Biomedical Co Ltd have been -25% over the past three years , -7% over the past five years .